BRPI0415053B8 - inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo - Google Patents

inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo

Info

Publication number
BRPI0415053B8
BRPI0415053B8 BRPI0415053A BRPI0415053A BRPI0415053B8 BR PI0415053 B8 BRPI0415053 B8 BR PI0415053B8 BR PI0415053 A BRPI0415053 A BR PI0415053A BR PI0415053 A BRPI0415053 A BR PI0415053A BR PI0415053 B8 BRPI0415053 B8 BR PI0415053B8
Authority
BR
Brazil
Prior art keywords
same
pharmaceutical composition
preparing
glycoprotein inhibitor
anticancer agent
Prior art date
Application number
BRPI0415053A
Other languages
English (en)
Inventor
Sun Lee Gwan
Chan Bang Keuk
Sup Kim Maeng
Young Cha Mi
Gil Ahn Young
Jin Ham Young
Original Assignee
Hanmi Holdings Co Ltd
Hanmi Science Co Ltd
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd, Hanmi Science Co Ltd, Hanmi Pharm Ind Co Ltd filed Critical Hanmi Holdings Co Ltd
Publication of BRPI0415053A publication Critical patent/BRPI0415053A/pt
Publication of BRPI0415053B1 publication Critical patent/BRPI0415053B1/pt
Publication of BRPI0415053B8 publication Critical patent/BRPI0415053B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo a biodisponibilidade de um agente anticancerígeno é aumentada quando o agente anticancerígeno é administrado junto com uma composição farmacêutica que compreende um composto de fórmula (i) ou um sal farmaceuticamente aceitável deste.
BRPI0415053A 2003-10-07 2004-10-06 inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo BRPI0415053B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020030069582A KR100557093B1 (ko) 2003-10-07 2003-10-07 다약제 내성 저해 활성을 갖는 테트라졸 유도체 및 그의제조방법
PCT/KR2004/002550 WO2005033097A1 (en) 2003-10-07 2004-10-06 P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same

Publications (3)

Publication Number Publication Date
BRPI0415053A BRPI0415053A (pt) 2006-11-28
BRPI0415053B1 BRPI0415053B1 (pt) 2019-12-31
BRPI0415053B8 true BRPI0415053B8 (pt) 2021-05-25

Family

ID=36500896

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415053A BRPI0415053B8 (pt) 2003-10-07 2004-10-06 inibidor de glicoproteína-p, método para preparar o mesmo e composição farmacêutica que compreende o mesmo

Country Status (23)

Country Link
US (1) US7625926B2 (pt)
EP (1) EP1678162B1 (pt)
JP (1) JP4481992B2 (pt)
KR (1) KR100557093B1 (pt)
CN (1) CN1863795B (pt)
AT (1) ATE466008T1 (pt)
AU (1) AU2004277475B2 (pt)
BR (1) BRPI0415053B8 (pt)
CA (1) CA2541301C (pt)
DE (1) DE602004026903D1 (pt)
DK (1) DK1678162T3 (pt)
ES (1) ES2342290T3 (pt)
HK (1) HK1096399A1 (pt)
IL (1) IL174665A (pt)
MX (1) MXPA06003803A (pt)
NO (1) NO336127B1 (pt)
NZ (1) NZ546257A (pt)
PL (1) PL1678162T3 (pt)
PT (1) PT1678162E (pt)
RU (1) RU2317985C1 (pt)
SI (1) SI1678162T1 (pt)
WO (1) WO2005033097A1 (pt)
ZA (1) ZA200603538B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0700773D0 (en) * 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
JP5330274B2 (ja) * 2007-03-01 2013-10-30 ノバルティス アーゲー Ｐｉｍキナーゼ阻害剤およびその使用方法
GB0706072D0 (en) * 2007-03-28 2007-05-09 Sterix Ltd Compound
BRPI0918268B1 (pt) 2008-09-02 2021-08-03 Novartis Ag Derivados de picolinamida, seu uso, e composição farmacêutica
KR101466245B1 (ko) * 2010-01-15 2014-12-01 한미사이언스 주식회사 테트라졸 메탄설폰산 염의 제조방법 및 이에 사용되는 신규 화합물
CN104334546B (zh) 2012-05-21 2017-05-03 诺华股份有限公司 作为激酶抑制剂的新的环‑取代的n‑吡啶基酰胺
KR101986683B1 (ko) * 2012-12-13 2019-06-10 한미약품 주식회사 테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
CN103804352B (zh) * 2014-01-23 2017-06-13 中国药科大学 三氮唑苯乙基四氢异喹啉类化合物及其制备方法和应用
KR20150135110A (ko) * 2014-05-23 2015-12-02 한미정밀화학주식회사 p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
CN104327046B (zh) * 2014-10-14 2017-11-17 中国药科大学 三氮唑‑n‑乙基四氢异喹啉类化合物及其制备方法和应用
JO3737B1 (ar) * 2015-07-21 2021-01-31 Athenex Therapeutics Ltd تركيبات علاجية من باكليتاكسيل تعطى عن طريق الفم ومثبط P-gp لعلاج السرطان
TWI752750B (zh) 2015-09-30 2022-01-11 香港商慧源香港創新有限公司 口服紫杉烷組合物及方法
WO2019200290A1 (en) * 2018-04-13 2019-10-17 Athenex Therapeutics Limited Therapeutic combinations of orally administered paclitaxel and a p-gp inhibitor for the treatment of angiosarcoma
CN113631166A (zh) * 2018-12-14 2021-11-09 慧源香港创新有限公司 用于治疗癌症的口服给药的伊立替康和P-gp抑制剂的治疗组合
AU2019397560A1 (en) 2018-12-14 2021-06-24 Athenex HK Innovative Limited Therapeutic combinations of orally administered Docetaxel and A P-gp inhibitor for the treatment of cancer
WO2020168144A1 (en) 2019-02-14 2020-08-20 Teva Pharmaceuticals International Gmbh Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(lh)- isoquinolinyl)ethyl] phenyl }-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl] -4- oxo-4h-chromene-2-carboxamide and of its mesylate salt
WO2020230037A1 (en) * 2019-05-13 2020-11-19 Dr. Reddy's Laboratories Limited Alternate process for the preparation of encequidar
WO2021044350A1 (en) * 2019-09-04 2021-03-11 Dr. Reddy’S Laboratories Limited Solid forms of encequidar mesylate and processes thereof
WO2022011221A1 (en) 2020-07-10 2022-01-13 Teva Czech Industries S.R.O Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5-dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide mesylate salt
JP2023544615A (ja) 2020-10-07 2023-10-24 アセネックス インコーポレイテッド アセトアミド－フェニルテトラゾール誘導体およびその使用方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE9190155U1 (de) * 1990-11-06 1993-10-07 Pfizer Chinazolinderivate zur Steigerung der Antitumoraktivität
JP3223193B2 (ja) 1991-08-09 2001-10-29 株式会社日清製粉グループ本社 インドール誘導体およびそれらを有効成分とする抗癌剤耐性克服物質
ATE152443T1 (de) 1992-07-10 1997-05-15 Glaxo Lab Sa Anilide-derivate
GB9717576D0 (en) 1997-08-19 1997-10-22 Xenova Ltd Pharmaceutical compounds
US20030220402A1 (en) * 2000-02-15 2003-11-27 Naoki Tsuchiya Cancer remedy comprising anthranilic acid derivatives as active ingredients
ATE423778T1 (de) 2002-05-14 2009-03-15 Xenova Ltd Verfahren zur herstellung von anthranilsäurederivat-hydrat
KR100580743B1 (ko) 2003-10-08 2006-05-15 한미약품 주식회사 다약제 내성 저해 활성을 갖는 신규한 크로몬 유도체 또는이의 약제학적으로 허용가능한 염 및 이들의 제조 방법

Also Published As

Publication number Publication date
AU2004277475B2 (en) 2007-08-09
DE602004026903D1 (de) 2010-06-10
MXPA06003803A (es) 2006-07-03
NZ546257A (en) 2009-09-25
DK1678162T3 (da) 2010-08-02
NO20062019L (no) 2006-07-06
NO336127B1 (no) 2015-05-18
EP1678162A1 (en) 2006-07-12
IL174665A0 (en) 2006-08-20
ATE466008T1 (de) 2010-05-15
CA2541301A1 (en) 2005-04-14
AU2004277475A1 (en) 2005-04-14
CA2541301C (en) 2010-02-02
RU2317985C1 (ru) 2008-02-27
HK1096399A1 (en) 2007-06-01
BRPI0415053B1 (pt) 2019-12-31
CN1863795A (zh) 2006-11-15
JP2007507493A (ja) 2007-03-29
EP1678162B1 (en) 2010-04-28
US7625926B2 (en) 2009-12-01
KR20050033734A (ko) 2005-04-13
US20070072900A1 (en) 2007-03-29
JP4481992B2 (ja) 2010-06-16
KR100557093B1 (ko) 2006-03-03
PT1678162E (pt) 2010-05-19
PL1678162T3 (pl) 2010-09-30
RU2006114427A (ru) 2007-11-20
BRPI0415053A (pt) 2006-11-28
ZA200603538B (en) 2007-09-26
SI1678162T1 (sl) 2010-07-30
IL174665A (en) 2012-10-31
CN1863795B (zh) 2011-05-18
WO2005033097A1 (en) 2005-04-14
ES2342290T3 (es) 2010-07-05
EP1678162A4 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
HK1096399A1 (en) P-glycoprotein inhibitor, method for preparing the same and pharmaceutical composition comprising the same p-
CY1116688T1 (el) Τροποποιητες φαρμακοκινητικων ιδιοτητων θεραπευτικων ειδων
RS52169B (en) STABLE LAKVINIMOD PREPARATIONS
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
ATE450533T1 (de) Carboxamidderivate
AR058433A1 (es) Derivado de 1,1-dioxido de 1,4-benzotiazepina ,procedimiento para su preparacion ,medicamentos que comprenden este compuesto y su uso
BR0208678A (pt) Composto, composição farmacêutica, uso de um composto
ATE472551T1 (de) Tocopherolmodifizierte therapeutische arzneimittelverbindung
BR0315296A (pt) Derivados do ciclohexanol espirocìclicos
EA200970585A1 (ru) Бензамидные производные как агонисты ер-рецепторов
EP1714961A4 (en) INDAZOL COMPOUND AND THEIR PHARMACEUTICAL USE
WO2005117895A3 (en) Compositions comprising meloxicam
SE0101932D0 (sv) Pharmaceutical combinations
ECSP045493A (es) Nuevas composiciones farmacéuticas que contienen flibanserina polimorfo a
BRPI0514250A (pt) uso de um composto, composição farmacêutica que compreende o mesmo, compostos e método de tratamento
NO20031410L (no) Anvendelse av distamycinderivater for fremstilling av medikamenter
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
MY139228A (en) Imidazolinylmethyl aralkylsulfonamides
WO2004048381A3 (en) Pyrazoloazepine compounds as pharmaceutical agents
WO2005097192A3 (en) Active substance combination of a carbinol compound and an opioid
AU2003281468A1 (en) P-glycoprotein inhibitor comprising octilonium bromide as an effective ingredient
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments
SE0004827D0 (sv) Therapeutic compounds
CO5580753A2 (es) Composicion farmaceutica que comprende un antagonista ltb4 y un inhibidor cox-2 o un inhibidor cox1/2
EA200401082A1 (ru) Новые соединения бензоиндолина, способ их получения и фармацевтические композиции, которые их содержат

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA INT.CL: C07D 401/14, A61P 35/00

Ipc: C07D 401/14 (2011.01)

B25A Requested transfer of rights approved

Owner name: HANMI HOLDINGS CO., LTD. (KR)

Free format text: TRANSFERIDO DE: HANMI PHARM. CO., LTD.

B25D Requested change of name of applicant approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B25G Requested change of headquarter approved

Owner name: HANMI SCIENCE CO., LTD. (KR)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 31/12/2019, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 06/10/2004 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF